Drug Profile
Research programme: DNA gyrase inhibitors - AstraZeneca
Alternative Names: Pyrrolamide-based antibacterials - AstraZenecaLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator AstraZeneca
- Class Amides; Naphthyridines; Pyrroles; Quinolines
- Mechanism of Action DNA gyrase inhibitors; DNA topoisomerase IV inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Bacterial infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Bacterial-infections in United Kingdom
- 04 Nov 2017 No recent reports of development identified for preclinical development in Bacterial-infections in USA
- 20 Sep 2011 Preclinical antimicrobial and pharmacodynamics data presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2011) ,